Altamira Therapeutics Ltd. (NASDAQ: CYTO) has reported a business update on Bentrio. Bentrio is a nasal spray for protection against airborne viruses and allergens. The company has contracts with wholesalers in Germany as it covers >50% of German pharmacies. Sales through these pharmacies represent majority of the OTC market in Germany and have been increasing as it is expected to boost further through marketing initiatives planned for the first quarter of 2022. Bentrio has become available in Germany via he Amazon platform as it pushes to strengthen its ecommerce influence.
The company has an open 510(k) submission within the United States. The United States Food and Drug Administration have initiated a substantive review of the company’s application for premarket clearance for protection against airborne allergies in mid-October.
“We are pleased to report further progress with the international roll-out of Bentrio, as well as with the further preclinical and clinical evaluation of Bentrio’s protective effects against airborne viruses and allergens,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO. “The rapid and global spread of the Omicron variant of SARS-CoV-2 is highlighting once more the need for simple, yet versatile protective measures to complement classic approaches such as vaccination, protective mask wearing or social distancing.”